Money
Filter News
Found 83,198 articles
-
Algernon Pharmaceuticals Announces Increase to Private Placement - December 27, 2023
12/27/2023
Algernon Pharmaceuticals Inc. a Canadian clinical stage pharmaceutical development company announces an increase to its non-brokered private placement, previously announced on December 12, 2023, from gross proceeds of $150,000 to $280,000 of units at an issue price of $0.075 per Unit.
-
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
12/27/2023
Avalo Therapeutics, Inc. announced a 1-for-240 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023.
-
Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.
12/27/2023
Visiox Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, and PowerUp Acquisition Corp. announced the execution of a definitive agreement for a business combination that would result in Visiox becoming a publicly traded company on the Nasdaq Capital Market.
-
Opthea to Receive US$35M Commitment and Additional US$50M Funding
12/27/2023
Opthea Limited announced that it expects to receive the remaining US$35 million committed funds under the Development Funding Agreement with Carlyle and Abingworth, and has entered into binding documentation with a new co-investor under an Amended DFA to secure an additional US$50 million in funding.
-
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
12/27/2023
Trevena Inc. announced that it has entered into definitive agreements for the issuance and sale of 2,779,906 shares of common stock of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share and associated warrant in a private placement, for expected gross proceeds to the Company of approximately $1.946 million.
-
Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
12/26/2023
Entera Bio Ltd., a leader in the development of orally delivered peptides and therapeutic proteins, announced that, on December 22, 2023, it closed a private placement with certain existing and new investors.
-
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
12/26/2023
Daré Bioscience, Inc. announced it has entered into a royalty-backed financing agreement that provides Daré with $5 million at closing and up to an additional $7 million through three tranches over time at Daré’s option.
-
Procaps Group Reports Third Quarter 2023 Results
12/26/2023
Procaps Group, S.A. announced its financial results for the three months ended September 30, 2023 and the nine months ended September 30, 2023.
-
BioSpace spoke with industry professionals about how to make your time in San Francisco valuable.
-
It has been a topsy-turvy year marked by record bankruptcies, a sharp drop in funding, few IPOs, and a steady stream of layoffs and regulatory challenges offset by M&A deals and the hot weight loss and antibody-drug conjugate markets.
-
Biotech Bankruptcies Skyrocket
12/22/2023
From Statera Biopharma and Sorrento Therapeutics to Aceragen and Infinity Pharmaceuticals, 2023 has seen a record high 28 bankruptcies in the biotech space so far. Here’s why. -
On January 4, 2024 BioSpace and guests from Halia Therapeutics, Triumvira Immunologics and the Alzheimer's Drug Discovery Foundation will discuss alternative financing strategies to consider for 2024. Subscribe and get notified when the event goes live.
-
Under the companies’ agreement, a previously disclosed option exercise fee of $75 million has been reduced to $10 million and the remaining pre-option development milestone has been removed.
-
Activist investor Elliott Investment Management has struck a deal with BioMarin and will add three people to its board of directors with a new stake in the company.
-
Medicenna Extends Period to Exercise Certain Warrants - December 22, 2023
12/22/2023
Medicenna Therapeutics Corp. announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of the common share purchase warrants of the Company originally issued on December 21, 2018.
-
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - December 22, 2023
12/22/2023
Iovance Biotherapeutics, Inc., a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, announced that on December 21, 2023, the Company approved the grant of inducement stock options covering an aggregate of 44,175 shares of Iovance’s common stock to four new non-executive employees.
-
Spyre Therapeutics Announces Grants of Inducement Awards - December 22, 2023
12/22/2023
Spyre Therapeutics, Inc. announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 411,000 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended.
-
Coherus BioSciences Announces New Employment Inducement Grants - December 22, 2023
12/22/2023
Coherus BioSciences, Inc., announced that effective December 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 192,000 shares of the common stock of the Company to five newly hired employees with a per share exercise price of $1.94, the closing trading price on the grant date.
-
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 22, 2023
12/22/2023
Madrigal Pharmaceuticals, Inc. announced that the company granted equity awards to thirty-two new employees with a grant date of December 19, 2023 as equity inducement awards outside of the Company’s Amended 2015 Stock Plan under the terms of the company's 2023 Inducement Plan.
-
Seelos Therapeutics, Inc. Releases Letter to its Stockholders - December 22, 2023
12/22/2023
Seelos Therapeutics, Inc. released a letter to its stockholders from Raj Mehra, Ph.D., Chairman and Chief Executive Officer of Seelos, the text of which is copied below.